Credit Suisse Ag Galectin Therapeutics Inc Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$1.96 - $2.57 $20,011 - $26,239	-10,210 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$2.24 - $2.87 $22,870 - $29,302	10,210 New	10,210 $23,000
Q3 2019 Nov 12, 2019	SELL	$3.0 - $4.05 $52,152 - $70,405	-17,384 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$3.61 - $5.0 $661,857 - $916,700	-183,340 Reduced 91.34%	17,384 $72,000
Q1 2019 May 14, 2019	BUY	$3.86 - $6.02 $774,794 - $1.21 Million	200,724 New	200,724 $1.03 Million

9.69M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.